CytoDyn Inc. (CYDY)
USD 0.23
(-1.61%)
USD 0.23
(-1.61%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 20.26 Million USD | -17.97% |
| 2023 | 32.87 Million USD | 0.94% |
| 2022 | 32.56 Million USD | 10.28% |
| 2021 | 29.53 Million USD | 2656.43% |
| 2020 | 1.07 Million USD | -80.96% |
| 2019 | 5.62 Million USD | 557.0% |
| 2018 | -1.23 Million USD | -71.76% |
| 2017 | -716.97 Thousand USD | 92.56% |
| 2016 | -9.64 Million USD | -399.25% |
| 2015 | 3.22 Million USD | 226.48% |
| 2014 | -2.54 Million USD | -283.71% |
| 2013 | 1.38 Million USD | 788.19% |
| 2012 | -201.49 Thousand USD | -231.61% |
| 2011 | 153.1 Thousand USD | 128.37% |
| 2010 | -539.57 Thousand USD | -731.81% |
| 2009 | 85.4 Thousand USD | -86.93% |
| 2008 | 653.33 Thousand USD | 12.94% |
| 2007 | 578.48 Thousand USD | 98.18% |
| 2006 | 291.9 Thousand USD | -53.75% |
| 2005 | 631.09 Thousand USD | 437.55% |
| 2004 | -186.96 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | 20.26 Million USD | -38.36% |
| 2024 Q1 | 31.31 Million USD | -4.75% |
| 2024 Q2 | 32.97 Million USD | 5.32% |
| 2024 Q3 | 29.08 Million USD | -11.81% |
| 2024 Q4 | 20.26 Million USD | -30.33% |
| 2023 Q4 | 32.87 Million USD | 5.3% |
| 2023 Q3 | 31.21 Million USD | -10.5% |
| 2023 Q1 | 32.54 Million USD | -0.07% |
| 2023 FY | 32.87 Million USD | 0.94% |
| 2023 Q2 | 34.88 Million USD | 7.18% |
| 2022 Q2 | 35.7 Million USD | -21.49% |
| 2022 FY | 32.56 Million USD | 10.28% |
| 2022 Q1 | 45.48 Million USD | 54.01% |
| 2022 Q4 | 32.56 Million USD | -6.62% |
| 2022 Q3 | 34.87 Million USD | -2.34% |
| 2021 FY | 29.53 Million USD | 2656.43% |
| 2021 Q3 | 24.45 Million USD | 12.88% |
| 2021 Q2 | 21.66 Million USD | 52.53% |
| 2021 Q1 | 14.2 Million USD | 1225.8% |
| 2021 Q4 | 29.53 Million USD | 20.75% |
| 2020 Q2 | 7.69 Million USD | 6.41% |
| 2020 Q4 | 1.07 Million USD | 136.52% |
| 2020 FY | 1.07 Million USD | -80.96% |
| 2020 Q1 | 7.22 Million USD | 28.46% |
| 2020 Q3 | -2.93 Million USD | -138.13% |
| 2019 Q3 | 6.1 Million USD | 26.51% |
| 2019 FY | 5.62 Million USD | 557.0% |
| 2019 Q4 | 5.62 Million USD | -7.8% |
| 2019 Q1 | 324.34 Thousand USD | 126.34% |
| 2019 Q2 | 4.82 Million USD | 1387.49% |
| 2018 Q2 | 4.09 Million USD | 15.41% |
| 2018 FY | -1.23 Million USD | -71.76% |
| 2018 Q4 | -1.23 Million USD | 75.11% |
| 2018 Q3 | -4.94 Million USD | -220.8% |
| 2018 Q1 | 3.54 Million USD | 594.93% |
| 2017 FY | -716.97 Thousand USD | 92.56% |
| 2017 Q4 | -716.97 Thousand USD | 90.8% |
| 2017 Q3 | -7.79 Million USD | 11.52% |
| 2017 Q2 | -8.81 Million USD | -98.26% |
| 2017 Q1 | -4.44 Million USD | 53.91% |
| 2016 FY | -9.64 Million USD | -399.25% |
| 2016 Q4 | -9.64 Million USD | 5.49% |
| 2016 Q3 | -10.2 Million USD | -213.67% |
| 2016 Q2 | -3.25 Million USD | -2145.06% |
| 2016 Q1 | 159.04 Thousand USD | -95.06% |
| 2015 Q4 | 3.22 Million USD | 3.61% |
| 2015 FY | 3.22 Million USD | 226.48% |
| 2015 Q1 | 398.78 Thousand USD | 115.65% |
| 2015 Q2 | 966.79 Thousand USD | 142.44% |
| 2015 Q3 | 3.1 Million USD | 221.66% |
| 2014 FY | -2.54 Million USD | -283.71% |
| 2014 Q2 | -7.7 Million USD | -517.26% |
| 2014 Q4 | -2.54 Million USD | 45.38% |
| 2014 Q1 | 1.84 Million USD | 33.14% |
| 2014 Q3 | -4.66 Million USD | 39.46% |
| 2013 Q1 | 17.32 Thousand USD | 108.6% |
| 2013 FY | 1.38 Million USD | 788.19% |
| 2013 Q4 | 1.38 Million USD | 424.22% |
| 2013 Q3 | 264.52 Thousand USD | 123.71% |
| 2013 Q2 | -1.11 Million USD | -6540.87% |
| 2012 FY | -201.49 Thousand USD | -231.61% |
| 2012 Q2 | 28.16 Thousand USD | 108.42% |
| 2012 Q3 | -1.69 Million USD | -6122.94% |
| 2012 Q4 | -201.49 Thousand USD | 88.12% |
| 2012 Q1 | -334.58 Thousand USD | -318.53% |
| 2011 Q3 | -320.8 Thousand USD | -651.28% |
| 2011 Q4 | 153.1 Thousand USD | 147.73% |
| 2011 Q1 | -250.92 Thousand USD | 53.5% |
| 2011 FY | 153.1 Thousand USD | 128.37% |
| 2011 Q2 | 58.19 Thousand USD | 123.19% |
| 2010 Q1 | 130.52 Thousand USD | 52.83% |
| 2010 Q4 | -539.57 Thousand USD | 30.29% |
| 2010 FY | -539.57 Thousand USD | -731.81% |
| 2010 Q2 | 99.01 Thousand USD | -24.14% |
| 2010 Q3 | -774.02 Thousand USD | -881.69% |
| 2009 Q2 | 656.88 Thousand USD | -4.88% |
| 2009 Q1 | 690.59 Thousand USD | 5.7% |
| 2009 FY | 85.4 Thousand USD | -86.93% |
| 2009 Q4 | 85.4 Thousand USD | -87.23% |
| 2009 Q3 | 668.77 Thousand USD | 1.81% |
| 2008 Q1 | 299.62 Thousand USD | -48.21% |
| 2008 Q4 | 653.33 Thousand USD | -13.25% |
| 2008 Q3 | 753.09 Thousand USD | 154.75% |
| 2008 Q2 | 295.62 Thousand USD | -1.34% |
| 2008 FY | 653.33 Thousand USD | 12.94% |
| 2007 Q1 | -35.8 Thousand USD | -112.27% |
| 2007 Q3 | 365.8 Thousand USD | 74.29% |
| 2007 Q4 | 578.48 Thousand USD | 58.14% |
| 2007 FY | 578.48 Thousand USD | 98.18% |
| 2007 Q2 | 209.89 Thousand USD | 686.25% |
| 2006 Q4 | 291.9 Thousand USD | -30.06% |
| 2006 Q1 | 473.87 Thousand USD | -24.91% |
| 2006 Q2 | 437.41 Thousand USD | -7.69% |
| 2006 Q3 | 417.35 Thousand USD | -4.59% |
| 2006 FY | 291.9 Thousand USD | -53.75% |
| 2005 Q2 | -14.83 Thousand USD | 80.59% |
| 2005 FY | 631.09 Thousand USD | 437.55% |
| 2005 Q3 | 52.00 USD | 100.35% |
| 2005 Q1 | -76.43 Thousand USD | 59.12% |
| 2005 Q4 | 631.09 Thousand USD | 1213551.92% |
| 2004 Q2 | 94.51 Thousand USD | 197006.25% |
| 2004 Q3 | -174.61 Thousand USD | -284.75% |
| 2004 FY | -186.96 Thousand USD | 0.0% |
| 2004 Q1 | -48.00 USD | 0.0% |
| 2004 Q4 | -186.96 Thousand USD | -7.07% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 1546817.557% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -258.723% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 52.651% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 8217.138% |
| Rebus Holdings, Inc. | 305 Thousand USD | -6543.279% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 421.388% |
| Qrons Inc. | 351.42 Thousand USD | -5665.636% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -3155.651% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 53.35% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 99384.594% |
| Skye Bioscience, Inc. | -5.72 Million USD | 454.145% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -28.542% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -392.032% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -4942.192% |
| SQZ Biotechnologies Company | -36.23 Million USD | 155.914% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -803.653% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -2085.322% |
| Mesoblast Limited | 55.85 Million USD | 63.726% |
| Marizyme, Inc. | 18.56 Million USD | -9.117% |
| Genus plc | 190.6 Million USD | 89.369% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -806.24% |
| Pharming Group N.V. | 109.8 Million USD | 81.547% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -2255.386% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -1569.182% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -2879.706% |
| ContraFect Corporation | -6.02 Million USD | 436.243% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -14949.131% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -1653.634% |
| IMV Inc. | 7.67 Million USD | -164.154% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -268.273% |
| MultiCell Technologies, Inc. | 90.04 USD | -22503231.853% |
| ONE Bio Corp. | 9.04 Million USD | -124.136% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 2860.573% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -56.512% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -1381.172% |
| Q BioMed Inc. | 4.06 Million USD | -399.063% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 33.685% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -1910.686% |
| Biomind Labs Inc. | 711.4 Thousand USD | -2748.179% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 66.534% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -913.408% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -58.215% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -5532.871% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -14393.148% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -101888.222% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -820.171% |
| GB Sciences, Inc. | 1.74 Million USD | -1059.607% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 11124.659% |
| HST Global, Inc. | 96.79 Thousand USD | -20833.332% |
| CSL Limited | 10.52 Billion USD | 99.808% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -9725.572% |
| Halberd Corporation | 144.72 Thousand USD | -13900.732% |
| Enzolytics Inc. | 981.65 Thousand USD | -1964.063% |
| Agentix Corp. | 37.63 Thousand USD | -53743.905% |
| Resverlogix Corp. | 6.45 Million USD | -214.091% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 3110.3% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.999% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 143.1% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -186.552% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -648.058% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 329.21% |
| AVAX Technologies, Inc. | -5.9 Million USD | 443.237% |
| Zenith Capital Corp. | 10.06 Thousand USD | -201231.479% |
| Genscript Biotech Corporation | -1.06 Billion USD | 101.909% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -10009.164% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -749.192% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -12216.651% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 110712.512% |
| Kadimastem Ltd | -253.1 Thousand USD | 8105.468% |
| Helix BioMedix, Inc. | -2.57 Million USD | 888.395% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 0.069% |
| BioStem Technologies, Inc. | 4.47 Million USD | -353.085% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -9967.874% |
| LadRx Corporation | -2.03 Million USD | 1094.957% |
| Cell Source, Inc. | 9.23 Million USD | -119.476% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -3090.027% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -3090.027% |
| NovAccess Global Inc. | 2.17 Million USD | -830.104% |
| Affymax, Inc. | -5.59 Million USD | 462.015% |
| Itoco Inc. | 228.3 Thousand USD | -8774.97% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -14799.735% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -308.755% |
| Mobile Lads Corp. | 484.23 Thousand USD | -4084.358% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 3131784.699% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 218715.2% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -162.938% |
| SYBLEU INC | 473.71 Thousand USD | -4177.264% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -354.608% |
| International Stem Cell Corporation | 2.59 Million USD | -682.317% |
| Bioxytran, Inc. | 1.89 Million USD | -967.031% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -32364.39% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -829.066% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -490.041% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -136.899% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -2522.549% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 1720.96% |
| Neutra Corp. | 52.18 Thousand USD | -38725.761% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 914.062% |
| PureTech Health plc | -167.19 Million USD | 112.119% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 8373.311% |
| IXICO plc | -4.44 Million USD | 555.88% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -53.279% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 63.06% |
| CSL Limited | 10.52 Billion USD | 99.808% |
| Cellectis S.A. | -43.81 Million USD | 146.24% |